Yongsheng Li

39PUBLICATIONS
65CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmacogenomicsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jul 24, 2026
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

|Jul 10, 2026
MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation.

|May 21, 2026
Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer.

|Mar 04, 2026
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Huaqiang Zhou, Hongyun Zhao, Xue Hou

|Jan 13, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Anna Li, Wei-Neng Feng, Juan Li

|Nov 25, 2025
Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells.

Yijiao Chen, Xudong Liu, Jiongming Chen

Pageof 7

Frequent Collaborators

4 joint publications

Lei Wu

3 joint publications

Wenfeng Fang

3 joint publications

Hongyun Zhao

3 joint publications

Li Zhang